Dr. Duncan Stearns - YouTube

Dr. Duncan S. Stearns

Claim this profile

Rainbow Babies and Childrens Hospital

Expert in Uterine Tumors
Expert in Neuroblastoma
57 reported clinical trials
118 drugs studied

About Duncan S. Stearns

Education:

  • Obtained MD from Case Western Reserve University School of Medicine in 2009.
  • Completed Residency in Pediatrics at Rainbow Babies and Children's Hospital in 2012.
  • Finished Fellowship in Pediatric Cardiology at Rainbow Babies and Children's Hospital in 2015.

Experience:

  • Serving as an Attending Physician in Pediatric Cardiology at Rainbow Babies and Children's Hospital since 2015.
  • Holds the position of Assistant Professor of Pediatrics at Case Western Reserve University School of Medicine.

Area of expertise

1Uterine Tumors
Global Leader
Duncan S. Stearns has run 19 trials for Uterine Tumors. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Neuroblastoma
Global Leader
Duncan S. Stearns has run 16 trials for Neuroblastoma. Some of their research focus areas include:
MYC positive
Stage IV
MYC negative

Affiliated Hospitals

Image of trial facility.
Rainbow Babies And Childrens Hospital
Image of trial facility.
Rainbow Babies & Children's Hospital

Clinical Trials Duncan S. Stearns is currently running

Image of trial facility.

Selumetinib vs. Chemotherapy

for Brain Cancer

This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Image of trial facility.

Inotuzumab Ozogamicin

for Acute Lymphoblastic Leukemia

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3

More about Duncan S. Stearns

Clinical Trial Related7 years of experience running clinical trials · Led 57 trials as a Principal Investigator · 19 Active Clinical Trials
Treatments Duncan S. Stearns has experience with
  • Cyclophosphamide
  • Radiation Therapy
  • Etoposide
  • Doxorubicin Hydrochloride
  • Nivolumab
  • Vincristine Sulfate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Duncan S. Stearns specialize in?
Is Duncan S. Stearns currently recruiting for clinical trials?
Are there any treatments that Duncan S. Stearns has studied deeply?
What is the best way to schedule an appointment with Duncan S. Stearns?
What is the office address of Duncan S. Stearns?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security